These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35767280)

  • 1. Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden.
    Raj SKS; Routh ED; Chou JW; Votanopoulos KI; Triozzi PL; Miller LD
    Cancer; 2022 Sep; 128(17):3254-3264. PubMed ID: 35767280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlate tumor mutation burden with immune signatures in human cancers.
    Wang X; Li M
    BMC Immunol; 2019 Jan; 20(1):4. PubMed ID: 30634925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
    Liu J; Xu W; Li S; Sun R; Cheng W
    Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
    [No Abstract]   [Full Text] [Related]  

  • 4. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
    Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
    BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer.
    Sammons S; Elliott A; Barroso-Sousa R; Chumsri S; Tan AR; Sledge GW; Tolaney SM; Torres ETR
    Front Oncol; 2023; 13():1235902. PubMed ID: 37637072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
    Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
    Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden.
    Lin J; Lin Y; Huang Z; Li X
    Comput Math Methods Med; 2020; 2020():8836493. PubMed ID: 33273963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
    Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
    Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptome Analysis of Tumor-Infiltrating Lymphocytes Identifies NK Cell Gene Signatures Associated With Lymphocyte Infiltration and Survival in Soft Tissue Sarcomas.
    Judge SJ; Bloomstein JD; Sholevar CJ; Darrow MA; Stoffel KM; Vick LV; Dunai C; Cruz SM; Razmara AM; Monjazeb AM; Rebhun RB; Murphy WJ; Canter RJ
    Front Immunol; 2022; 13():893177. PubMed ID: 35874727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort.
    Bevins N; Sun S; Gaieb Z; Thorson JA; Murray SS
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
    Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
    Front Immunol; 2022; 13():943389. PubMed ID: 36003381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
    Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
    Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prognostic Value of Tumor Mutation Burden and Immune Cell Infiltration in Thymic Epithelial Tumors.
    Du H; Xie S; Guo W; Zhang W; Che J; Zhu L; Hang J
    Ann Clin Lab Sci; 2021 Jan; 51(1):44-54. PubMed ID: 33653780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer.
    Cheng Y; Bu D; Zhang Q; Sun R; Lyle S; Zhao G; Dong L; Li H; Zhao Y; Yu J; Hao X
    J Adv Res; 2023 Sep; 51():121-134. PubMed ID: 36351537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational burden and signatures in 4000 Japanese cancers provide insights into tumorigenesis and response to therapy.
    Hatakeyama K; Nagashima T; Ohshima K; Ohnami S; Ohnami S; Shimoda Y; Serizawa M; Maruyama K; Naruoka A; Akiyama Y; Urakami K; Kusuhara M; Mochizuki T; Yamaguchi K
    Cancer Sci; 2019 Aug; 110(8):2620-2628. PubMed ID: 31152682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
    Wang L; Yao Y; Xu C; Wang X; Wu D; Hong Z
    Technol Cancer Res Treat; 2021; 20():15330338211052154. PubMed ID: 34806485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
    Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
    Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma.
    He M; Abro B; Kaushal M; Chen L; Chen T; Gondim M; Yan W; Neidich J; Dehner LP; Pfeifer JD
    Hum Pathol; 2020 Jun; 100():15-23. PubMed ID: 32387103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.